Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Thursday 10th August 2023 at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter ended as on 30th June, 2023. The board meeting concluded on 06.30 P.M. Please take the above intimation in your records. Thanking You,

pdf

Johnson Pharmacare Ltd.

03 Aug 2023

Board Meeting

Johnson Pharmacare Ltd - 532154 - Board Meeting Intimation for Compliance Of Regulation 29 Of SEBI …

BSE India

Johnson Pharmacare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2023 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that a meeting of the Board of Directors of the Company will be held on Thursday 10th August 2023 inter alia, to consider following business. - 1.) To approve and take on record the Un-Audited Financial Results of the Company for the quarter ended on 30th June 2023. 2.) Any other matter with the permission of the board which the Board may think fit. Please take the above intimation in your records. Thanking You.

pdf

Johnson Pharmacare Ltd.

04 Jul 2023

Company Update

Johnson Pharmacare Ltd - 532154 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Please find Enclosed

pdf

Johnson Pharmacare Ltd.

30 Jun 2023

SAST

Johnson Pharmacare Ltd - 532154 - Closure of Trading Window

BSE India

Please Find Enclosed

pdf

Johnson Pharmacare Ltd.

24 May 2023

Result

Johnson Pharmacare Ltd - 532154 - Regulations 30, 33 And Other Applicable Provisions Of The SEBI …

BSE India

This is to inform you that Outcome of the Board Meeting of the Company held on Wednesday 24th May 2023 in accordance with SEBl (Listing Obligations and Disclosures Requirements) Regulations, 2015, has been approved by the Board of Directors of the Company and taken on record inter-alia the following items; 1.) Consideration and Approval of Audited Financial Result for the Year ended 31st March, 2023. 2.) Independent Audit Report in pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 for the F.Y. 31st March, 2023. Further, we hereby declare that the Auditor of the Company has issued the Audit report under the Companies Act, 2013 and financial results as prepared under SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 for the financial year ended on March 31, 2023 with unmodified opinion. The board meeting concluded on 04.00 P.M

pdf

Johnson Pharmacare Ltd.

24 May 2023

Board Meeting

Johnson Pharmacare Ltd - 532154 - Board Meeting Outcome for Outcome Of The Board Meeting Of …

BSE India

pdf

Johnson Pharmacare Ltd.

24 May 2023

Annual Report

Annual report for Johnson Pharmacare Ltd. for FY-2023

None

pdf

Johnson Pharmacare Ltd.

18 May 2023, 02:32PM

Board Meeting

Johnson Pharmacare Ltd - 532154 - Board Meeting Intimation for Compliance Of Regulation 29 Of SEBI …

BSE India

Johnson Pharmacare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2023 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday 24th May 2023 at registered office of the company inter alia, to consider following business. 1. Approve and take on record the Audited Standalone Financial Results of the Company for the quarter and year ended on 31st March 2023. 2. Any other matter which the Board may think fit. Please take the above intimation in your records. Thanking You.

pdf

Is Sun and Shine Worldwide Ltd. worth buying?

222 Votes:

Buy 70.27%

Sell 9.01%

Hold 20.72%